SCHEMBL2635486

SCHEMBL2635486

COC(=O)c1cc(OCC(=O)NCCc2ccccc2)c2c(Cl)cc(Cl)cc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
ALDH1A1 P00352 2/20 0.53
HTT P42858 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C19 P33261 2/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
MAPT P10636 2/20 0.49
TP53 P04637 1/20 0.49
ESR1 P03372 1/20 0.47
YWHAB P31946 1/20 0.47
PDK1 Q15118 1/20 0.47
PKM P14618 1/20 0.47
GAA P10253 1/20 0.46
PTPN1 P18031 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
MGLL Q99685 1/20 0.45
KDM5B Q9UGL1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2635529 0.91 ALDH1A1 (0.56) LMNAL3MBTL1ALDH1A1HTTCYP1A2
SCHEMBL2636251 0.90 RAB9A (0.56) LMNAL3MBTL1ALDH1A1HTTMAPT
SCHEMBL2635555 0.83 MAPT (0.52) LMNAL3MBTL1ALDH1A1HTTCYP1A2
SCHEMBL12003984 0.82 ANO1 (0.47) LMNAL3MBTL1ALDH1A1HTTCYP1A2
SCHEMBL2635632 0.82 ALDH1A1 (0.50) LMNAALDH1A1CYP2C19CYP2C9MAPT
SCHEMBL2635943 0.81 TDP1 (0.49) ALDH1A1CYP2C19MAPTSMN1; SMN2HPGD
SCHEMBL2636337 0.81 ANO1 (0.47) LMNAALDH1A1HTTMAPTGAA
SCHEMBL2635556 0.80 RAB9A (0.59) LMNAL3MBTL1ALDH1A1HTTMAPT
SCHEMBL2635722 0.79 LMNA (0.38) LMNAALDH1A1HTTCYP3A4MAPT
SCHEMBL2636335 0.79 MEN1 (0.47) LMNAALDH1A1HTTMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220577-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA 2012-08-30 US disclosed
EP-2438037-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2012-04-11 EP disclosed
WO-2010139481-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220577-A1 GLYCINE B ANTAGONISTS GLRB, GRIN2B, GLRA2 LMNA 1894/4885L3MBTL1 1436/4885ALDH1A1 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.